Abstract: We reviewed the pathogenesis, clinical presentation, treatment options and outcomes of prostatic abscess in the post-antibiotic era, focusing on how patient risk factors and the emergence of multidrug-resistant organisms influence management of the condition. A MEDLINE search for "prostate abscess" or "prostatic abscess" was carried out. Prostate abscess is no longer considered a consequence of untreated urinary infection; now, men with prostatic abscess are typically debilitated or immunologically compromised, with >50% of patients having diabetes. In younger men, prostatic abscess can be the initial presentation of such chronic conditions. In older men, prostatic abscess is increasingly a complication of benign prostatic hyperplasia or prostate biopsy. Diagnosis is based on a physical examination, leukocytosis, leukocyturia and transrectal ultrasound, with magnetic resonance imaging serving as the preferred confirmatory imaging modality. Treatment of prostatic abscess is changing as a result of the emergence of atypical and drug-resistant organisms, such as extended-spectrum blactamase-producing enterobacteriaceae and methicillin-resistant Staphylococcus aureus. As many as 75% of infections are resistant to first-generation antibiotics, necessitating aggressive therapy with broad-spectrum parenteral antibiotics, such as third-generation cephalosporins, aztreonam or antibiotic combinations. A total of 80% of patients require early surgical drainage, frequently through a transurethral approach. In the postantibiotic era, prostatic abscess is evolving from an uncommon complication of urinary infection to a consequence of immunodeficiency, growing antibiotic resistance and urological manipulation. This condition, primarily affecting patients with chronic medical conditions rendering them susceptible to atypical, drug-resistant organisms, requires prompt aggressive intervention with contemporary antibiotic therapy and surgical drainage.
Introduction
PA is a localized collection of purulent fluid within the prostate, often as a complication of ABP. 1 In 1842, W Allison first reported a fatal case of PA with spontaneous urethral rupture into the rectoprostatic fossa. 2 Similar reports from the 19th century emphasized the still-relevant difficulties in distinguishing abscess from ABP, and described associations with urinary obstruction, gonorrheal infection and immunodeficiency, although these were not recognized as such at the time. In the early 1900s, the recognition of drainage as the mainstay of management led to the description of several surgical approaches, with most clinicians adopting direct perineal prostotomy over blind puncture with urethral sounds or external urethrotomy. [3] [4] [5] [6] In this era, mortality was high, ranging from 6% to 30%; 7 survival was fraught with complications of both the disease and treatment. In the 1930s, sulfanilamide brought antimicrobials into the treatment realm, but antibiotics were not effective until the introduction of penicillin. 8 This and derivative drugs controlled antecedent infections, decreasing abscess incidence in atrisk populations. In the 1970s, the development of continuous-flow low-pressure cystoscopic resection allowed transurethral abscess unroofing under direct vision. 9 The widespread availability of ultrasound in the 1980s revolutionized PA diagnosis and allowed the guidance of percutaneous drainage. 10 Although these combined advances made PA a rare disease with reduced mortality (3-16%) in healthy men, they have changed the nature of PA. 11 No longer associated with an antecedent history of gonorrhea, new at-risk populations have emerged who present with a wide range of localized and systemic signs and symptoms that prove challenging for prompt diagnosis and management.
Although the mainstay of treatment remains drainage and antibiotic therapy, no consensus exists about methodology or timing. In the present review, we discuss the presentation, diagnostic challenges, decision-making process and sequela of PA in the post-antibiotic era.
Etiology and natural history
PA is commonly a complication of ABP, thought to occur through reflux of infected urine contents into prostatic ducts. Risk factors for abscess reflect those for ABP and chronic bacterial prostatitis, including primarily voiding dysfunction as a result of severe BPH or other forms of bladder outlet obstruction, indwelling urethral catheters and neurogenic voiding dysfunction. 12 The incidence of PA peaks in the fifth and sixth decades, but can affect males of all ages, including neonates 13, 14 and rarely, adolescents. 15 No recent studies have addressed disease incidence: in the 1990s, PA was estimated to affect 0.2-0.5% of males, 16, 17 comprising 0.5-2.5% of all prostatic disease. 16 With new advances in care extending longevity, PA is evolving into a new clinical entity, primarily affecting patients with chronic medical conditions. Although still rare among young, healthy men, the incidence is rising in patients with diabetes, chronic renal failure, cirrhosis, pyogenic liver abscess, cancer requiring chemotherapy, organ transplants, rheumatologic conditions and HIV/AIDS. The incidence of PA is estimated at 3% in asymptomatic HIV-positive men, and in 14% of men with AIDS. 18 The presence of PA in younger men with no risk factors should prompt evaluation for previously undiagnosed comorbidities. Studies have reported that 17-25% of patients presenting with PA were newly diagnosed with diabetes at that presentation. 19, 20 This group tended to be younger than those with known risk factors, reflecting both the decreasing age of diabetes onset in the USA, and limited access to screening and preventative care in at-risk populations.
Men undergoing genitourinary instrumentation constitute another unique group at risk for PA. More than 1 million patients undergo transrectal prostate biopsy each year. These patients, who are frequently older with coincident outlet obstruction, are at risk for PA from direct introduction of bacteria into the prostate. Along with multiple case reports, [21] [22] [23] [24] previous cross-sectional studies have shown that 8-11% of patients presenting with PA had recently undergone prostate biopsies. 25, 26 In two such cases, PA was the result of infection with multidrug-resistant Escherichia coli. 21, 23 As patients undergoing transrectal prostate biopsy are frequently given antimicrobial prophylaxis, it is important to be mindful of the rising emergence of multidrug resistance in post-prostate biopsy infections. 27 Novel gland-conserving therapies directed at prostate cancer, such as cryotherapy 28 and brachytherapy, 29 are also associated with rare complications of PA; several reports also detail PA after intravesical BCG for bladder cancer. [30] [31] [32] [33] This complication must be considered in patients presenting with suspicious symptoms after urological instrumentation.
Causative organisms
Before antibiotics, PA was most commonly a complication of gonorrheal infection in previously healthy men. 6 Frequently complicated by spontaneous rupture into the urethra, rectum or perineum, these infections were associated with a 50% mortality rate. 5 Staphylococcus aureus was the other common causative organism, typically from hematogenous spread in patients with rheumatic fever, extensive furunculosis, chronic gingivitis or osteomyelitis. 6 The advent of antibiotics resulted in a predominance of Gram-negative bacteria as the most common organism seen in 60-80% of PA. 34 Neisserial infections are now rare; E. coli is the most common pathogen in both ABP and PA. In the 1970s, approximately 75% of these infections were susceptible to first-generation antibiotics; now, only approximately 20% are susceptible. 20 S. aureus remains the most common hematogenously spread infection leading to PA. Increasing cases as a result of MRSA, both nosocomial and community-acquired, [35] [36] [37] are a growing concern, with >30 cases of PA as a result of S. aureus (methicillin-resistant and -sensitive) reported in the literature. 38 Other reported bacterial pathogens include Klebsiella pneumoniae, [39] [40] [41] Enterococcus species, 34, 42, 43 Streptococcus species, 44 Pseudomonas aeruginosa, 45 Bukholderia pseudomallei [46] [47] [48] and Brucella melitensis. 49 Atypical organisms are seen more frequently in the severely immunocompromised, such as post-transplant and AIDS patients, 18 and include pathogens seen at a higher incidence in those populations, such as mycobacteria (Mycobacterium avium intracellulare, mTB 50, 51 ), as well as pathogenic fungi, such as Coccidioides immitis, 52 Candida species, [53] [54] [55] Cryptococcus neoformans, 20, 56 Blastomyces dermatitidis,
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Histoplasma capsulatum 58, 59 and Cladophialophora carrionii. 60 Although rare overall, there have been numerous reports of PA formation as a result of disseminated mTB amongst HIV/immunocompromised patients, patients with previous BCG therapy and, infrequently, immunocompetent patients. 50 This might be of particular importance, as rates of mTB cases increase internationally, along with the emerging concern of multi-drug resistant tuberculosis in HIV/mTB coinfected patients. 61 
Presentation
The common presenting symptoms of PA are similar to ABP, including dysuria, urgency, frequency, the sensation of incomplete voiding, suprapubic or perineal pain and tenesmus. Rarely, patients display terminal hematuria or frank drainage of pus per urethra. 12 Urinary retention occurs in as many as one-third of patients when the abscess is large enough to cause outflow obstruction. Focal symptoms, however, might be absent. As many as one-third of patients will present with systemic symptoms only, such as fever of unknown origin, malaise or frank sepsis. 12 More than 96% of patients, however, manifest more than one symptom; in a series of 269 patients, just two had no symptoms at all and were discovered incidentally on transrectal ultrasound carried out for other indications.
11
Approximately one-quarter of patients acquire abscesses by hematogenous spread, and might show signs and symptoms attributable to other infectious foci, including furuncles, abrasions, bronchitis, otitis, appendicitis, diverticulitis, or perirectal or perirenal abscesses. Patients with systemic infections, such as tuberculosis, candidiasis or melioidosis, might have perineal pain or dysuria as only one of a constellation of complaints.
On physical examination, >95% of patients will complain of a painful prostate on DRE. While fluctuance on DRE is reported as pathognomonic for PA, the incidence of fluctuance ranges from 16-88% throughout the literature.
11,62 A number of other conditions can present with this finding, such as prostatic cyst, granuloma, m€ ullerian duct cyst or seminal vesicle cyst and cystic neoplasms of the prostate. Frank urethral discharge in PA is rare and, in non-gonorrheal infections, typically results from spontaneous rupture into the urethra. More than 90% of patients will have a leukocytosis on laboratory studies; almost all will display leukocyturia. 17 Approximately half of patients will have a positive urine culture, but the significance of this result is unclear; approximately half of these cultures will show a different organism from the one obtained from procedural specimens. 18, 20 PA can also develop as a result of a urinary tract infection with gas-forming organisms, for which patients with poorlycontrolled diabetes mellitus are particularly at risk. 63 The first case series of EPA was published in 1983. 64 Although EPA cases are only a small portion of all PA cases, this disease subset is associated with rapid disease progression, delayed diagnosis and high mortality rates (25%). 63, 65 Presentations of EPA include urinary tract infections with dysuria, frequency and urgency, accompanied by fever, acute urinary retention, perineal pain, tenesmus and pelvic discomfort. 63 Air in the bladder wall can be visualized on pelvic X-ray, underscoring the utility of a radiological examination in this subset of PA.
Given the wide range of non-specific presenting symptoms, PA is often mistaken for ABP or UCPPS. With a prevalence of approximately 10% for UCPPS in the male population, indolent PA can be easily missed. 66, 67 If a patient, especially one with known immunodeficiency, is worsening or failing to improve with antibiotic treatment, we recommend proceeding to a definitive evaluation. Imaging remains the best diagnostic modality to prevent unnecessary delays in treatment.
Imaging modalities
TRUS is the most common and inexpensive method available, providing an accurate diagnosis in 80-100% of patients. 20, 42, 68 This technique is preferable to transperineal or transabdominal ultrasound, as TRUS involves direct contact with the prostate and resolution by intervening surfaces is not limited. Abscesses most commonly appear as hypoechoic (anechoic to isoechoic) areas, often of varying sizes, containing thick liquid with internal septations. Abscesses are typically located in the transitional and central zones, and can distort the anatomy of the gland. Intraglandular calcifications are common. TRUS can be used for initial diagnosis, therapeutic intervention and monitoring of recovery, all without radiation exposure. One recent report even outlined a clinical classification scheme based on TRUS findings to facilitate and standardize diagnosis, localization and management of PA. 69 For radiologists and urologists comfortable with this imaging modality, TRUS is an effective, safe and economical method of evaluating PA. 70 However, TRUS is contraindicated in patients with anal fistulas and severe hemorrhoids, and can be highly painful for some patients with PA.
CT should be used selectively when the diagnosis is in question. It allows visualization of direct extraprostatic spread, and might identify other sites of necrotizing infection when hematogenous spread is suspected. The study should be carried out with and without intravenous contrast, as areas with poor perfusion within the prostate can appear isodense on non-contrast images. Although many physicians are more comfortable with this modality, there is no general advantage to CT; TRUS is more effective for visualizing intraprostatic abscesses. 71 It is difficult to distinguish small abscesses from cystic nodules of BPH on CT, as the hallmark of surrounding fatty inflammation might be absent in the prostate. CT will detect reactive lymphadenopathy, which could provide a clue to the diagnosis, but is non-specific. CT should only be used if TRUS cannot be carried out due to patient pain or discomfort, although transabdominal or transperineal ultrasound can also be attempted in thin patients. CT, however, seems to be the diagnostic modality of choice for EPA, as it allows for clear visualization of gas and fluid accumulation in the prostate gland. 63, 65 TRUS can be used to confirm findings from CT.
Recent advancements in ultrasonography could further improve the utility of transrectal imaging. A recent study evaluating TRSS, which provides real-time, multidimensional and high-resolution images, was successful in diagnosing PA in a group of 18 patients. 72 TRSS can also be used for therapeutic interventions for PA, such as transperineal needle aspiration and transurethral unroofing for PA recurrences.
MRI has better inherent tissue contrast resolution than CT, and new advances have improved its sensitivity further, even without use of an endorectal coil. On MRI, abscesses show iso-to hypointense signal with peripheral contrast enhancement on T1-weighted images, and heterogeneous hyperintense signal on T2-weighted images (Fig. 1) . 73 Although diagnostic accuracy is better than that of CT, it has not been shown to be more sensitive than TRUS, suggesting that TRUS remains first-line. 73 MRI might be helpful, however, in the early stages of abscess formation, when TRUS is inconclusive. 74 Use of diffusion-weighted imaging might also help distinguish abscesses from cystic carcinomas. Although the signal-to-noise ratio is improved 10-fold with use of an endorectal coil, patients with PA might not tolerate its placement, and it is usually not necessary with modern high-field (1.5 or 3.0 Tesla) scanners, except in patients with an exceptionally large abdominal circumference.
Management
Small abscesses might be amenable to a trial of conservative therapy in patients who are not clinically ill. No standard of care exists, but common regimens have historically included quinolones with prostatic penetration, such as ciprofloxacin, although concerns over the safety of these antibiotics, as expressed by the recent U.S. Food and Drug Administration Boxed Warning, 75 and increasing resistance rates 76 might caution against their first-line use. Although antibiotics can be safely given on an outpatient basis for ABP, inpatient stay might be warranted for PA, which can progress rapidly to sepsis. If the patient is debilitated or immunocompromised, more aggressive treatment is warranted, given concern for atypical or resistant organisms. Possible parenteral regimens might include a third-generation cephalosporin, aztreonam or the combination of an aminoglycoside with ampicillin. Patients should be monitored during initial treatment; if no clinical improvement is noted, there should be a low threshold to change regimens and proceed to surgical intervention. In general, antibiotics remain an adjunct to drainage, as most patients will require surgery. Antibiotics alone should only be attempted in stable patients with abscesses <1 cm with serial imaging to ensure resolution. 77 Seven out of nine patients with PA underwent surgical intervention; 78 several other large case studies similarly report a majority of patients requiring surgical management for PA. 77, 79 For many providers, transrectal ultrasound-guided aspiration of the abscess is the first-line of therapy. 19, 68 Some physicians utilize a preparatory regimen of preoperative enema and antibiotics similar to that used for prostate biopsy, but this is not universal. TRUS-guided aspiration is carried out transrectally using a large-bore needle (e.g. 20-cm long 18-G Chiba-type needle). During aspiration, the abscess cavity is monitored for decreasing size (Fig. 2) . Drainage can be carried out transperineally, 80 but no evidence supports this technique as superior; 81, 82 in fact, reports have detailed the development of periurethral or perineal abscesses after perineal aspiration requiring open incision and drainage. 18 As most urologists are comfortable with the transrectal approach, we recommend this as the standard for ultrasound-guided drainage. 25, 68 Of the multiple advantages to this technique, foremost is the ability to carry out aspiration at the bedside with local anesthesia. Drainage can be carried out at initial assessment, allowing the practitioner to diagnose and intervene in one procedure, and can be repeated in case of recurrence. The incidence of infectious complications after TRUS-guided aspiration is low, but can be severe; in several series, low rates of severe, even fatal, sepsis have been reported despite adequate abscess drainage. 20, 34 There is one report of rectourethral fistula formation after aspiration. 25 The greatest limitation to this method remains to be abscess recurrence and/or incomplete treatment. PA is often multifocal and loculated, with thick, purulent fluid that can be difficult to drain by aspiration. Studies examining recurrence after aspiration disagree, ranging from 15% to 33%. 12, 17, 34, 79 Based on outcomes from several large case series studies, some authors recommend the use of TRUS-guided aspiration before progressing to other therapies. 25, 68 For patients with large, multiloculated infections, transurethral unroofing of PA might be more appropriate; up to one- third of patients with PA will eventually require transurethral resection of the prostate. 20, 26 Other indications for transurethral unroofing with resection of the prostate include prostate sizes of ≥80 g, recurrent or residual abscesses (such as those following incomplete resolution after aspiration), associated BPH and persistent lower urinary tract symptoms. 25, 26, 83 Under cystoscopic vision, after determining by imaging where the abscess cavity is located relative to the prostatic urethra, a wire loop or Collins knife is used to unroof the abscess cavity ( Fig. 3; Video S1 ). As abscesses are not always visible by cystoscopy, we recommend carrying out extensive resection of both lateral lobes to drain any loculations. In patients with known obstructive BPH, complete transurethral resection of the prostate is beneficial at draining the abscess, addressing the risk of recurrent infections and relieving obstructive symptoms. Postoperatively, a Foley catheter is left in place to drain pus and infected urine. The catheter can be removed in 7 days or after fever and bleeding resolve. This method has a much lower rate of recurrence; one study reported a need for abscess re-treatment in 7% of patients who had previously undergone unroofing. 25 Although transient bacteremia after transurethral procedures is common, worsening septicemia after unroofing is rare. 20, 25 This procedure bears the same risks as a transurethral resection of the prostate, including retrograde ejaculation, urethral stricture and incontinence. These risks might sway patients toward needle aspiration, particularly those who desire fertility. Transurethral resection also requires a formal operation with anesthesia, which might be risky in patients who are hemodynamically unstable, and bears a higher risk of bleeding, especially in patients with hematological abnormalities, such as the platelet dysfunction commonly seen in sepsis. Transurethral resection of the prostate, however, was associated with significantly shorter hospitalization lengths when compared with needle aspiration. 79 Transurethral holmium laser deroofing of PA has also been reported as an alternative to loop transurethral drainage, with successful outcomes and no recurrence in a study of eight patients with multiloculated PA. 43 Lee et al. describe transurethral unroofing using a holmium laser. An initial incision into the abscess cavity is made with a holmium laser at the 5 or 7 o'clock position. An additional incision can be made if required for complete drainage. Incisions are deepened to open the abscess cavity and allow for pus drainage. 43 Other methods include open perineal drainage, which should be reserved for patients with extraprostatic involvement. 77 In addition to a long convalescence, there is a significant risk of impotence. As most patients have underlying compromised immune systems, it is best to avoid open procedures, given poor wound healing and the potential for superinfection. 18 Historically, indwelling drains have also been utilized; however transurethral unroofing and TRUS-guided aspiration are now considered the standard of treatment. In fact, several authors have published treatment algorithms for the management of PA. 25, 68, 77 Although recommendations differ slightly, it seems most amenable to carry out surgical interventions (TRUS-guided aspiration, transurethral resection of the prostate) for patients with large abscesses.
Although each of these approaches has risks, the consequences of delaying treatment can be worse. While infertility from ejaculatory dysfunction might result from intervention, it can also result from abscess expansion. When not rapidly addressed, PA can rupture, leading to extension into the perirectal space or perineum, requiring open incision and drainage. Even when managed appropriately, abscess rupture carries a risk of fistula formation to skin or adjacent viscera. 20 Progression to hematogenous spread can produce distant visceral infections or shower septic emboli throughout the body (Fig. 4) . 84 Ascent of the infection in the urinary Fig. 3 Transurethral unroofing of prostatic abscess under direct cystoscopic vision. A complete transurethral resection of the prostate was performed to address the bilateral, loculated abscess cavities seen above by MRI (see Fig.  2 ) and to prevent recurrence of obstructive symptoms. During resection of the left lateral lobe of the prostate using a wire loop, the abscess cavity at the left posteriolateral apex was unroofed, resulting in emanation of thick purulent drainage (black arrow). tract can cause pyelonephritis and renal impairment. Bacteremia is also a concern, and risk factors include, but are not limited to, immunosuppression, such as HIV or transplantation; diabetes; cancer; urinary retention; indwelling catheter; and patients undergoing treatment. Most important is the increased risk of sepsis and death, the inevitable conclusion to unrecognized disease.
Discussion
In an era of heavy antibiotic use, PA is rare, occurring primarily in debilitated and immunocompromised men. Where gonorrheal infections were once the most common cause, diabetes is now the most common predisposing factor for PA, seen in 42-59% of patients. 20, 25, 68, 79 PA is rare in healthy men without underlying risk factors, but can be the first presenting sign of underlying chronic disease. Given barriers to care for the socially disadvantaged, clinicians must have a high suspicion for an underlying comorbidity in previously healthy patients who present with PA.
In addition to the new challenge of treating infectious disease in an immunocompromised population, treatment of PA is complicated by a lack of high-quality evidence on which to base clinical decisions. Case reports and reviews make up the large majority of published data regarding PA, with just a few case series reported. This lack of prospective treatment and epidemiological data has prevented the development of diagnostic and treatment guidelines, and has limited our understanding of the true incidence of PA and its associated microbial and host risk factors.
PA can frequently be misdiagnosed as either ABP or UCPPS. Despite the rarity of PA and the wide range of presenting symptoms, it is important to consider this disease in any patient, with or without risk factors, with acute-onset irritative or obstructive voiding symptoms that do not respond to antibiotics. The natural history of this disease is changing; delays in care result in more severe complications as a result of poor functional reserve and atypical infections. Obtaining cultures with antibiotic susceptibilities from surgical specimens is crucial; urine culture is often inaccurate, and causative organisms are often drug-resistant. Clinicians should also have a low threshold to change antibiotic treatments quickly when no clinical response is observed, regardless of culture results.
Adequate treatment requires accurate diagnosis and rapid treatment, typically involving surgical intervention. Imaging should not be delayed if there is any suspicion of PA. Historically, several imaging methods have been utilized to diagnose PA, including DRE, CT, MRI and TRUS. Increasing evidence points to the emergence of TRUS as the first-line diagnostic modality for PA; however, CT and MRI can be used if TRUS is inconclusive or cannot be carried out, or when dealing with abscesses that have extended beyond the prostate. 7, 68, 77 TRUS is an easy, bedside method that can be used effectively to diagnose, treat (aspiration) and follow clinical progression. This approach is preferable in young men wishing to preserve continence and fertility when no outlet obstruction is present. Because of the possibility of recurrence, however, we recommend transurethral unroofing of the abscess whenever patients are septic or have larger, multiloculated collections, regardless of age. As the new face of PA is a manifestation of underlying debilitation and immunocompromise, recovery requires effective treatment of the patient's comorbidities. Good glycemic control in diabetes, renal replacement in chronic renal failure and management of uremia in liver failure must be achieved to ensure good outcomes. 85 
Conclusions
In the post-antibiotic era, PA has changed from a disease of young sexually active men to one of the debilitated and immunocompromised. Although antibiotics serve an important adjunct function in treatment, appropriate management requires both early diagnosis and surgical drainage. Whenever this clinical entity is encountered, it must serve as a red flag to the clinician either to evaluate for undiagnosed underlying comorbidities or to initiate more aggressive management to control a known chronic illness.
